Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
Our commitment to endocrinology
Ipsen continues to develop innovative medicines in endocrinology, with specific investment in pituitary pathologies and growth disorders.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
- @IpsenGroup RT @EFPIA: CAR-T cell therapies could help patients avoid a lifetime of treatment. Find out more: https://t.co/Mq4MkYsLdu #WeWontRest https…
- @IpsenGroup Thank you to @IKCCORG and everyone for raising awareness on #KidneyCancer #WKCD2017 https://t.co/sAhQC23JwL https://t.co/VdIVqkb48S
- @IpsenGroup Knowledge saves lives. Thank you @IKCCORG for putting #KidneyCancer on the map! Let's keep working together!… https://t.co/PNC0pu7Xb0
- @IpsenGroup Today is World Kidney Cancer Day. Take the quiz and share with us what you learned! #wkcd2017 cc @IKCCORG https://t.co/71HFTtF4IR
RESEARCH & DEVELOPMENT
Our commitment is based on a strengthened partnership policy, a promising pipeline, two specialized technological platforms and three benchmark R&D centers across the globe.